Vidan Diagnostics

Vidan Diagnostics is an early-stage, private diagnostics company targeting the urgent need for improved Diabetic Ketoacidosis (DKA) management. Its core asset is the Beta-Hydroxybutyrate 21FS test, which measures blood levels of beta-hydroxybutyrate (BHB), the primary ketone body in DKA, offering a more specific and reliable diagnostic marker than traditional methods. The company is likely in a pre-revenue, development stage, aiming to commercialize a product that could enable faster diagnosis, better treatment guidance, and reduced healthcare costs in emergency and point-of-care settings. Success will depend on securing regulatory clearance, demonstrating clinical utility, and navigating a competitive landscape with established and emerging ketone testing solutions.

Diagnostic assay for the quantitative measurement of beta-hydroxybutyrate (BHB) in blood, targeting laboratory or point-of-care use for Diabetic Ketoacidosis.

The ketone testing market is competitive, featuring consumer-focused urine strips (e.g., Bayer), prescription blood ketone meters for home use (e.g., Abbott's Precision Xtra), and laboratory methods from major IVD players like Roche, Siemens Healthineers, and Abbott Laboratories. Vidan must differentiate by offering superior analytical performance, seamless lab integration, or a compelling cost-benefit argument to capture market share in the hospital setting.